Last reviewed · How we verify
Benralizumab Arm C
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA).
At a glance
| Generic name | Benralizumab Arm C |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | IL-5 receptor antagonist monoclonal antibody |
| Target | IL-5 receptor alpha (IL-5Rα) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Respiratory |
| Phase | Phase 3 |
Mechanism of action
Benralizumab targets interleukin-5 receptor alpha (IL-5Rα), a key receptor on eosinophils and basophils that mediates their survival and activation. By blocking this receptor, the drug induces rapid eosinophil apoptosis and reduces circulating and tissue eosinophil populations. This mechanism effectively suppresses eosinophil-driven inflammatory responses in conditions like severe eosinophilic asthma.
Approved indications
- Severe eosinophilic asthma
- Eosinophilic granulomatosis with polyangiitis (EGPA)
Common side effects
- Headache
- Nasopharyngitis
- Pyrexia
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |